Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Moskowitz.
Osteoarthritis. Diagnosis and medical/surgical management.
3re ed., Sunders, (2001),
[2.]
R. Loeser, N. Shakoor.
Aging or osteoarthritis: which is the problem?.
Rheum Dis Clin N Am, 29 (2003), pp. 653-673
[3.]
A. Mannoni, M.P. Briganti, M. Di Bari, L. Ferrucci, S. Costanzo.
Epidemiological profile of symptomatic osteoarthritis in older adults: a population based study in Dicomano, Italy.
Ann Rheum Dis, 62 (2003), pp. 576-578
[4.]
Y. Zhang, J. Niu, M. Kelly-Hayes, C.E. Chaisson, P. Aliabadi, D.T. Felson.
Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The Framingham Study.
Am J Epidemiol, 156 (2002), pp. 1021-1027
[5.]
M.C. Nevitt, L. Xu, Y. Zhang, L.Y. Lui, W. Yu, N.E. Lane, et al.
Very low prevalence of hip osteoarthritis among Chinese elderly in Beijing, China, compared with whites in the United States: the Beijing osteoarthritis study.
Arthritis Rheum, 46 (2002), pp. 1773-1779
[6.]
D.T. Felson, M.C. Nevitt, Y. Zhang, P. Aliabadi, B. Baumer, D. Gale, et al.
High prevalence of lateral knee osteoarthritis in Beijing Chinese compared with Framingham Caucasian subjects.
Arthritis Rheum, 46 (2002), pp. 1217-1222
[7.]
R. Espinosa, L. Hernández, C. Arroyo.
Prevalencia de manifestaciones musculoesqueléticas en México.
Rev Mex Reumatol, 20 (2005), pp. 5
[8.]
M.H. Cardiel, J. Rojas-Serrano.
Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study.
Clin Exp Rheumatol, 20 (2002), pp. 617-624
[9.]
R. Altman, G. Alarcón, D. Appelrouth, D. Bloch, D. Boreinstein, K. Brandt, et al.
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand.
Arthritis Rheum, 33 (1990), pp. 601-610
[10.]
R. Altman, G. Alarcón, D. Appelrouth, D. Bloch, D. Boreinstein, K. Brandt, et al.
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip.
Arthritis Rheum, 34 (1991), pp. 505-514
[11.]
R. Altman, E. Asch, D. Bloch, G. Bole, D. Boreinstein, K. Brandt, et al.
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee.
Arthritis Rheum, 29 (1986), pp. 1039-1049
[12.]
J. Woo, E. Lau, C.H. Sing, P. Lee, J. Zhang, T. Kwok, et al.
Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services, and direct and indirect costs.
Arthritis Care Res, 49 (2003), pp. 526-534
[13.]
L. Carmona, J. Ballina, R. Gabriel, A. Laffon, EPISER Study Group.
The burden of musculoskeletal diseases in the general population of Spain: results from a national survey.
Ann Rheum Dis, 60 (2001), pp. 1040-1045
[14.]
R. Espinosa, L. Hernández, C. Arroyo.
Patrón de utilización de servicios de salud en México en pacientes con artritis.
Rev Mex Reumatol, 20 (2005), pp. 20-21
[15.]
S. Bollen.
Epidemiology of knee injuries: diagnosis and triage.
Br J Sports Med, 34 (2000), pp. 227-228
[16.]
J.E. Manson, S.S. Bassuk.
Obesity in the United States: a fresh look at its high toll.
JAMA, 289 (2003), pp. 229-230
[17.]
C.L. Hill, S.G. Suk, D. Gale, S. Totterman, M.E. Gale, D.T. Felson.
Cruciate ligament integrity in osteoarthritis of the knee.
Arthritis Rheum, 52 (2005), pp. 794-799
[18.]
M. Reijman, J.M.W. Hazes, H.A.P. Pols, B.W. Koes, S.M.A. Bierma-Zeinstra.
Acetabular dysplasia predicts incident osteoarthritis of the hip: the Rotterdam study.
Arthritis Rheum, 52 (2005), pp. 787-793
[19.]
D.T. Felson.
Risk factors for osteoarthritis: understanding joint vulnerability.
Clin Orthop Relat Res, 427 (2004), pp. 16-21
[21.]
C. Slemenda, K.D. Brandt, D.K. Heilman, S. Mazzuca, E.M. Braunstein, B.P. Katz, et al.
Quadriceps weakness and osteoarthritis of the knee.
Ann Intern Med, 127 (1997), pp. 97-104
[22.]
E. Superio-Cabuslay, M.M. Ward, K.R. Loring.
Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory dug treatment.
Arthritis Care Res, 9 (1996), pp. 292-301
[23.]
S.A. Mazzuca, K.D. Brandt, B.P. Katz, M.P. Hanna, C.A. Mefi.
Reduced utilization and cost of primary care clinic visits resulting from self-care education for patients with osteoarthritis of the knee.
Arthritis Rheum, 42 (1999), pp. 1267-1273
[24.]
S.A. Mazzuca, K.D. Brandt, B.P. Katz, M. Chambers, D. Byrd, M. Hanna.
Effects of self-care education on the health status of inner-city patients with osteoarthritis of the knee.
Arthritis Rheum, 40 (1997), pp. 1466-1474
[25.]
M. Weinberger, V.W. Tierney, P. Booher, B.P. Katz.
Can the provision of information to patients with osteoarthritis improve functional status? A randomized, controlled trial.
Arthritis Rheum, 32 (1989), pp. 1577-1583
[26.]
D.T. Felson, J.J. Anderson, A. Naimark, A.M. Walker, R.F. Melnan.
Obesity and knee osteoarthritis.
Ann Intern Med, 109 (1988), pp. 18-24
[27.]
D.T. Felson, Y. Zhang, M.T. Hannan, J.J. Anderson.
Risk factors for incident radiographic knee osteoarthritis in the elderly.
Arthritis Rheum, 40 (1997), pp. 728-733
[28.]
S. Tepper, M.C. Hochberg.
Factors associated with hip osteoarthritis: data from the First National Health and Nutrition Examination Survey (NHANES I).
Am J Epidemiol, 137 (1993), pp. 1081-1088
[29.]
W.J. Carman, M. Sowers, V.M. Hawthorne, L.A. Weissfeld.
Obesity as a risk factor for osteoarthritis of the hand and wrist: a prospective study.
Am Med J Epidemiol, 139 (1994), pp. 119-129
[30.]
D.T. Felson, Y. Zhang, J.M. Anthony, A. Naimark, J.J. Anderson.
Weigth loss reduces the risk of symptomatic knee osteoarthritis in women.
Ann Intern Med, 116 (1992), pp. 535-539
[31.]
E. Roddy, W. Zhang, M. Doherty.
Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review.
Ann Rheum Dis, 64 (2005), pp. 544-548
[32.]
S.A. Brand, R.D. Crowninshield.
The effect of cane use on hip contact force.
Clin Orthop, 147 (1980), pp. 181-184
[33.]
E.M. Keating, P.M. Faris, M.A. Ritter, J. Kane.
Use of lateral heel and sole wedges in the treatment of medial osteoarthritis of the knee.
Orthop Rev, 22 (1993), pp. 921-924
[34.]
R. Marks, A.H. Quinney, J. Wessel.
Reliability and validity of measurement of position sense in women with osteoarthritis of the knee.
J Rheumatol, 20 (1993), pp. 1919-1924
[35.]
J. Cushnagan, C. MacCarthry, P.A. Dieppe.
Taping the patella medially: a new treatment for osteoarthritis of the knee joint?.
Br Med J, 308 (1988), pp. 753-755
[36.]
W.Y. Zhang, A. Li-Wan-Po.
The effectiveness of topically applied capsaicin. A meta-analysis.
Eur J Clin Pharmacol, 46 (1994), pp. 517-522
[37.]
Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. BMJ.
[38.]
K.M. Jordan, N.K. Arden, M. Doherty, B. Bannwarth, J.W. Bijlsma, P. Dieppe, et al.
EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).
Ann Rheum Dis, 62 (2003), pp. 1145-1155
[39.]
American College of Rheumatology.
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines.
Arthritis Rheum, 43 (2000), pp. 1905-1915
[40.]
W. Zhang, A. Jones, M. Doherty.
Does paracetamol (acetaminophen) reduces the pain of osteoarthritis? A meta-analysis of randomized placebo controlled trials.
Ann Rheum Dis, 63 (2004), pp. 901-907
[41.]
P. Amadio, D.M. Cummings.
Evaluation of acetaminophen in the management of osteoarthritis of the knee.
Curr Ther Res, 34 (1983), pp. 59-66
[42.]
M. Zoppi, G. Peretti, E. Boccard.
Placebo-controlled study of the analgesic efficacy of an effervescent formulation of 500 mg paracetamol in arthritis of the knee or hip.
Eur J Pain, 16 (1995), pp. 42-48
[43.]
C. Miceli-Richard, M. Le Bars, N. Schmidely, M. Dougados.
Paracetamol in osteoarthritis of the knee.
Ann Rheum Dis, 63 (2004), pp. 923-930
[44.]
T. Pincus, G. Koch, H. Lei, B. Mangal, T. Sokka, R. Moskowitz, et al.
Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomized, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.
Ann Rheum Dis, 63 (2004), pp. 931-939
[45.]
R. Neame, W. Zhang, M. Doherty.
Historic issue of the annals: three papers examines paracetamol in osteoarthritis.
Ann Rheum Dis, 63 (2004), pp. 897-900
[46.]
T. Pincus, J.F. Fort, B. Mangal, G. Koch, F. Wolfe, R. Moskowitz, et al.
Patient Preference for Placebo, Acetaminophen (paracetamol), or Celebrex Effectiveness Study (PACES-1): a double-blinded, randomized, crossover clinical trial in patients with osteoarthritis of the hip or knee [resumen].
Ann Rheum Dis, 62 (2003), pp. 73
[47.]
H.J. Williams, J.R. Ward, M.J. Egger, R. Neuner, R.H. Brooks, D.O. Clegg, et al.
Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee.
Arthritis Rheum, 36 (1993), pp. 1196-1206
[48.]
J.D. Bradley, K.D. Brandt, B.P. Katz, L.A. Kalasinski, S.I. Ryan.
Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic.
J Rheumatol, 19 (1992), pp. 1950-1954
[49.]
T. Pincus, G.G. Koch, T. Sokka.
A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee.
Arthritis Rheum, 44 (2001), pp. 1587-1598
[50.]
G.P. Geba, A.L. Weaver, A.B. Polis, M.E. Dixon, T.J. Scnitzer, Vioxx ACT (VACT) Group. Vioxx ACT (VACT) Group.
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
JAMA, 287 (2002), pp. 64-71
[51.]
T.J. Schnitzer, M. Kamin, W.H. Olson.
Tramadol allows reduction of naproxen dose among patientes with naproxen-responsive osteoarthritis pain.
Arthritis Rheum, 42 (1999), pp. 1370-1377
[52.]
W.S. Mullican, J.R. Lacy.
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the managament of chronic pain: a comparative trail.
Clin Ther, 23 (2001), pp. 1429-1445
[53.]
J.P. Case, A.J. Baliunas, J.A. Block.
Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium.
Arch Intern Med, 163 (2003), pp. 169-178
[54.]
J.A. Chard, D.J. Tallon, P.A. Dieppe.
Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint.
Ann Rheum Dis, 59 (2000), pp. 414-418
[55.]
M.r. Tramer, R.A. Moore, D.J. Reyanolds, H.J. McQuay.
Quantitative estimation of rare adverse events which follow biological progression: a new model applied to chronic NSAID use.
Pain, 85 (2000), pp. 169-182
[56.]
A.G. Johnson, NSDAIDs and increased blood pressure.
What is the clinical significance?.
Drug Saf, 17 (1997), pp. 277-289
[57.]
G.S. Bleumink, J. Feenstra, M.C. Sturkenboom, B.H. Stricker.
Nonsteroidal anti-inflammatory drugs and heart failure.
Drugs, 63 (2003), pp. 525-534
[58.]
A. Whelton.
Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.
Am J Med, 106 (1999), pp. 13-24
[59.]
P. Courtney, M. Doherty.
Key questions concerning paracetamol and NSAIDs for osteoarthritis.
Ann Rheum Dis, 61 (2002), pp. 767-773
[60.]
K.D. Brandt.
Non-surgical treatment of osteoarthritis: a half century of “advances”.
Ann Rheum Dis, 63 (2004), pp. 117-122
[61.]
J.M. Bjordal, A.E. Ljunggren, A. Klovning, L. Slørdal.
Non-steroidal antiinflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomized placebo controlled trials.
BMJ, 329 (2004),
[62.]
F.E. Silverstein, D.Y. Graham, J.R. Senior, H.W. Davies, B.J. Struthers, R.M. Bittman, et al.
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non steroidal antiinflammatory drugs. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med, 123 (1995), pp. 241-249
[63.]
N.D. Yeomans, Z. Tulassay, L. Juhasz, I. Racz, J.M. Howard, C.J. Van Rensburg, et al.
A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs.
N Engl J Med, 338 (1998), pp. 719-726
[64.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus.
Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[65.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med, 343 (2000), pp. 1520-1528
[66.]
T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, J.R. Vane.
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.
Proc Natl Acad Sci U S A, 96 (1999), pp. 7563-7568
[67.]
C. Fenton, G.M. Keating, A.J. Wagstaff.
Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.
Drugs, 64 (2004), pp. 1231-1261
[68.]
J.E. Edwards, H.J. McQuay, R.A. Moore.
Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
Pain, 111 (2004), pp. 286-296
[70.]
C.C. Hawkey, P. Svoboda, I.F. Fiedorowicz-Fabrycy, E.L. Nasonov, E.G. Pikhlak, M. Cousin, et al.
Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis.
J Rheumatol, 31 (2004), pp. 1804-1810
[71.]
Food and Drugs Administration. Disponible en: http://www.fda.gov/cder/drug/infopage/COX2/default.htms
[72.]
R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators, et al.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
N Engl J Med, 352 (2005), pp. 1092-1102
[73.]
D.J. Graham, D. Campen, R. Hui, M. Spence, C. Cheetham, G. Levy, et al.
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
Lancet, 365 (2005), pp. 475-481
[74.]
N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, et al.
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
N Engl J Med, 352 (2005), pp. 1081-1091
[75.]
S.R. Knowles, E.J. Phillips, G. Wong, N.H. Shear.
Serious dermatologic reaction associated with valdecoxib: report of two cases.
J Am Acad Dermatol, 51 (2004), pp. 1028-1029
[76.]
W. Zhang, M. Doherty, N. Arden, B. Bannwarth, J. Bijlsma, K.P. Gunther, et al.
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Ann Rheum Dis, 63 (2004), pp. 11-14
[77.]
J.Y. Reginster, R. Leroisy, L.C. Rovati.
Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial.
Lancet, 357 (2001), pp. 251-256
[78.]
K. Pavelka, J. Gatterova, M. Olejarova, S. Machacek, G. Giacovelli, L.C. Rovati.
Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.
Arch Intern Med, 162 (2002), pp. 2113-2123
[79.]
F. Richy, O. Bruyere, O. Ethgen, M. Cucherat, Y. Henrotin, J.Y. Reginster.
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis.
Arch Intern Med, 163 (2003), pp. 1514-1522
[80.]
T.E. McAlindon, M.P. LaValley, J.P. Gulin, D.T. Felson.
Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis.
JAMA, 283 (2000), pp. 1469-1475
[81.]
B.A. Michel, G. Stucki, D. Frey, F. De Vathaire, E. Vignon, P. Bruehlmann, et al.
Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial.
Arthritis Rheum, 52 (2005), pp. 779-786
[82.]
M. Yaron, I. Shirazi, I. Yaron.
Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures.
Osteoarthritis Cartilage, 7 (1999), pp. 272-280
[83.]
N. Felisaz, K. Boumediene, C. Ghayor, J.F. Herrouin, P. Bogdanowicz, et al.
Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1.
Osteoarthritis Cartilage, 7 (1999), pp. 255-264
[84.]
J.P. Pelletier, M. Yaron, B. Haraoui, P. Cohen, M.A. Nahir, D. Choquette, et al.
Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group.
Arthritis Rheum, 43 (2000), pp. 2339-2348
[85.]
M. Dougados, M. Nguyen, L. Berdah, B. Mazieres, E. Vignon, M. Lequesne.
Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip.
Arthritis Rheum, 44 (2001), pp. 2539-2547
[86.]
T. Appelboom, J. Schuermans, G. Verbruggen, Y. Henrotin, J.Y. Reginster.
Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study.
Scand J Rheumatol, 30 (2001), pp. 242-247
[87.]
M. Lequesne, E. Maheu, C. Cadet, R.L. Dreiser.
Structural effect of avocado/ soybean unsaponifiables on joint space loss in osteoarthritis of the hip.
Arthritis Rheum, 47 (2002), pp. 50-58
[88.]
Y.E. Henrotin, C. Sánchez, M.A. Deberg, N. Piccardi, G.B. Guillou, P. Msika, et al.
Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and pro-inflammatory mediator production by human osteoarthritic chondrocytes.
J Rheumatol, 30 (2003), pp. 1825-1834
[89.]
C. Kut-Lasserre, C.C. Miller, A.L. Ejeil, B. Gogly, M. Dridi, N. Piccardi, et al.
Effect of avocado and soybean unsaponifiables on gelatinase A (MMP-2), stromelysin 1 (MMP-3), and tissue inhibitors of matrix metalloproteinase (TIMP-1 and TIMP-2) secretion by human fibroblasts in culture.
J Periodontol, 72 (2001), pp. 1685-1694
[90.]
E. Ernst.
Avocado-soybean unsaponifiables (ASU) for osteoarthritis- a systematic review.
Clin Rheumatol, 22 (2003), pp. 285-288
[91.]
C.V. Little, T. Parsons.
Herbal therapy for treating osteoarthritis.
Cochrane Database Syst Rev, 1 (2001),
[92.]
K. Walker-Bone.
“Natural remedies” in the treatment of osteoarthritis.
Drugs Aging, 20 (2003), pp. 517-526
[93.]
M.C. Hochberg, R.D. Altman, K.D. Brandt, B.M. Clark, P.A. Dieppe, M.R. Griffin, et al.
Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology.
Arthritis Rheum, 38 (1995), pp. 1541-1546
[94.]
G. Papachristou, S. Anagnostou, T. Katsorhis.
The effect of intra-articular hydrocortisone injection on the articular cartilage of rabbits.
Acta Orthop Scand, (1997), pp. 132-134
[95.]
P. Creamer.
Intra-articular corticosteroid treatment in osteoarthritis.
Curr Opin Rheumatol, 11 (1999), pp. 417-421
[96.]
J.P. Raynauld, C.H. Buckland-Wright, R. Ward, D. Choquette, B. Haraoui, J. Martel-Pelltier, et al.
Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee. A randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 48 (2003), pp. 370-377
[97.]
J.G. Peyron.
Intraarticular hyaluronan injections in the tratment of osteoarthritis: state-of-the art review.
J Rheumatol, 20 (1993), pp. 10-15
[98.]
Dougados M. Gossec.
Intra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying.
Ann Rheum Dis, 63 (2004), pp. 478-482
[99.]
I. Pasquali-Ronchetti, D. Guerra, F. Taparelli, F. Boraldi, G. Bergamini, G. Mori, et al.
Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis.
Rheumatology Oxford, 40 (2001), pp. 158-169
[100.]
G.H. Lo, M. Lavalley, T. MacAlidon, D.T. Felson.
Intraarticular hyaluronic acid in treatment of knee osteoarthritis. A meta-analysis.
JAMA, 290 (2003), pp. 3115-3121
[101.]
C.T. Whang, J. Lin, C.J. Cang, Y.T. Lin, S.M. Hou.
Therapeutics effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials.
J Bone Joint Surg, 84 (2004), pp. 538-545
[102.]
M. Wobig, G. Bach, P. Beks, A. Dickut, J. Runzheimer, G. Schwieger, et al.
The role of elastoviscocity in the efficacy of viscosupplemetation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower molecular weight hyaluronan.
Clin Ther, 21 (1999), pp. 1549-1562
[103.]
V. Listrat, X. Ayral, F. Paternella, J.P. Bonvarlet, J. Simonnet, B. Amor, et al.
Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee.
Osteoarthritis Cartilage, 5 (1997), pp. 153-160
[104.]
R.W. Jubb, S. Piva, L. Beinat, J. Dacre, P. Gishen, on behalf of the UK Hyalgan Study Group.
Structure modification in osteoarthritis with intra- articular sodium Hyaluronate of man. 500-730 KDa.
Ann Rheum Dis, 60 (2001), pp. 46.
[105.]
J. Arrich, F. Piribauer, P. Mad, D. Schmid, K. Klaushofer, M. Mullner.
Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis.
CMAJ, 172 (2005), pp. 1039-1043
[106.]
F.J. Blanco-García.
Manual SER de la artrosis. Sociedad Española de Reumatología.
1.ª ed., IM&C, (2002),
Copyright © 2005. Elsevier España S.L. Barcelona
